Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Shares Outstanding (Weighted Average) (2024 - 2025)

Prelude Therapeutics' Shares Outstanding (Weighted Average) history spans 2 years, with the latest figure at $77.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 1.52% year-over-year to $77.0 million; the TTM value through Dec 2025 reached $77.0 million, up 1.52%, while the annual FY2025 figure was $77.0 million, 1.52% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $77.0 million at Prelude Therapeutics, up from $76.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $77.0 million in Q4 2025 and bottomed at $75.7 million in Q1 2024.